文献速递垂体与肾上腺疾病

糖皮质激素替代治疗对继发性肾上腺皮质功能不全患者脂联素与HDL-C的影响

Glucocorticoid Replacement Affects Serum Adiponectin Levels and HDL-C in Patients With Secondary Adrenal Insufficiency.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

研究纳入58例非功能性垂体腺瘤患者分析ITT皮质醇峰值与脂联素及HDL-C关系,另12例SAI患者随机交叉接受氢化可的松10、20、30mg/d各4周。结果示脂联素和HDL-C与ITT峰值皮质醇显著相关,SAI患者低于非SAI,且随氢化可的松剂量依赖性升高。

要点

  • SAI患者血清脂联素与HDL-C水平显著低于非SAI患者。
  • 氢化可的松替代使脂联素和HDL-C呈剂量依赖性升高。
  • ITT峰值皮质醇与脂联素及HDL-C显著相关。

核心结论

  • 糖皮质激素替代治疗可升高继发性肾上腺皮质功能不全患者的血清脂联素和HDL-C水平。

研究设计与样本

  • 第一部分为横断面研究,纳入58例接受胰岛素耐量试验评估肾上腺功能的非功能性垂体腺瘤患者。
  • 第二部分为随机双盲交叉研究,12例SAI患者随机接受氢化可的松10、20或30mg/d,每期4周,共三期。

主要发现

  • ITT后峰值皮质醇水平与血清脂联素和HDL-C显著相关。
  • SAI患者血清脂联素和HDL-C水平显著低于非SAI患者。
  • 氢化可的松替代治疗使血清脂联素和HDL-C呈剂量依赖性升高。

关键数值与推荐

  • 氢化可的松替代剂量为10、20、30mg/d,每期4周。
  • SAI诊断基于胰岛素耐量试验评估肾上腺功能。

临床怎么用

  • 在SAI患者中,糖皮质激素替代治疗可能通过升高脂联素和HDL-C影响心血管风险标志物。
  • 临床调整氢化可的松剂量时需考虑其对脂联素和HDL-C的剂量依赖性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Low serum adiponectin and high-density lipoprotein-cholesterol (HDL-C) levels are risk factors for cardiovascular disease. Patients with primary adrenal insufficiency are at higher risk of cardiovascular complications compared with healthy subjects. However, there is no information on the relationship between adiponectin and glucocorticoid replacement therapy in patients with secondary adrenal insufficiency (SAI). OBJECTIVE: To determine the effects of intrinsic adrenal function and glucocorticoid replacement therapy on serum adiponectin levels and lipid profile in patients with SAI. DESIGN: Part 1: a cross-sectional study. Part 2: a randomized, double-blind, crossover study. SETTING: Osaka University Hospital, Osaka, Japan. PATIENTS: Part 1: 58 patients diagnosed with nonfunctioning pituitary adenoma who underwent insulin tolerance test (ITT) for assessment of adrenal function. Part 2: 12 SAI patients randomly received hydrocortisone replacement therapy at a dose of 10, 20, or 30 mg/d for 4 weeks per term for three terms. OUTCOME MEASUREMENTS: Part 1: we analyzed the relationship between serum cortisol levels during ITT and serum adiponectin levels and the lipid profile. Part 2: serum adiponectin levels and lipid profile were measured every 4 weeks. RESULTS: Serum levels of adiponectin and HDL-C correlated significantly with peak cortisol levels after ITT. Serum adiponectin and HDL-C levels were significantly lower in patients with SAI than non-SAI. Serum levels of adiponectin and HDL-C increased in a hydrocortisone dose-dependent manner. CONCLUSIONS: Glucocorticoid replacement therapy increased serum levels of adiponectin, an adipose-derived anti-atherogenic factor, and HDL-C in patients with SAI.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hayashi R, Tamada D, Murata M, et al. Glucocorticoid Replacement Affects Serum Adiponectin Levels and HDL-C in Patients With Secondary Adrenal Insufficiency. J Clin Endocrinol Metab. 2019. PMID: 31290981. doi:10.1210/jc.2019-00420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。